Back Bay Life Science Report

Back Bay Life Science Report

Jonathan P. Gertler, MD and Peter Bak, PhD

Episodes 35
Avg. Duration 26m
Activity Highly Active
Apple Rating 4.0 (4)
Since Jun 2021
Latest Episode Apr 2026

Outreach Signals

Features Guests

Publishing Details

Schedule
Monthly
Format
Episodic
Consistency
69%
Hosting
feeds.transistor.fm

Contact & Outreach

About This Podcast

Back Bay Life Science Advisors brings you expert insights from our strategic advisors and investment bankers on biopharma, medtech, and medical device development, trends, and growth areas. On this podcast, you’ll hear from our experts in life science development, commercialization, and investment banking, scientific investigators, biotech and medtech executives, physicians, and strategists who excel at guiding global life sciences companies and their investors through complex decisions. Join us for insights generated from in-depth scientific, strategic, and financial analysis at the intersection of science and business.

Podcasting 2.0 Features

episode podping transcript

Social Media

Explore Statistics

Recent Episodes

Evolving Oncology: The Expanding Landscape of Targeted Therapies and Investment

Apr 15, 2026 30m

Examining the dynamic progress in targeted oncology, the episode delves into the shift from single-mutation therapies to broad pathway targeting, highlighting advances in EGFR, KRAS, and the MAPK…

ADC Revolution in Ovarian Cancer: Current Developments and Future Outlook

Mar 05, 2026 29m Transcript

As ovarian cancer research enters a pivotal new era, Back Bay Life Science Advisors' Dr. Pete Bak is joined by Director Mavra Nasir and Consultant Trent Gordon for a deep dive into one of oncology's…

2025 Drug Approval Review

Feb 09, 2026 28m

As the life sciences industry turns the page to 2026, Back Bay Life Science Advisors’ Dr. Pete Bak and Dr. Mavra Nasir take a detailed look back at FDA drug approvals in 2025, a year marked by…

A Capital Markets Outlook for 2025: 2024, A Year in Review

Feb 07, 2025 15m

In this DNB//Back Bay Healthcare Capital Markets podcast episode, Jim Cirenza, Head of Fixed Income and Equities at DNB, Kristoffer Braaten, Director and Head of Equity Capital Markets at DNB, and…

The Optimism of Bispecific Antibodies

Nov 08, 2024 26m

The topic of bispecific antibodies has been an area of interest in the pharma space for a long time now. The recent news of the notable late-stage data from Akeso and Summit’s PD-1/VEGF bispecific…

Dynamics in Healthcare Focused Markets

Sep 30, 2024 20m

In this DNB//Back Bay Healthcare Capital Markets Episode, Vasilios Kofitsas, Partner and Managing Director at Back Bay Life Science Advisors speaks with Jim Cirenza and Kristoffer Braaten of DNB Bank…

From NASH to MASH: Current Market Dynamics in Hepatology

Sep 16, 2024 28m

After a summer away from podcasting, Back Bay Life Science Advisors’ Dr. Pete Bak and Christian Thienel are back on the mic to discuss current market dynamics in liver disease with a focus on one of…

Key Considerations for a US Healthcare IPO

May 22, 2024 35m

In this DNB//Back Bay Healthcare Capital Markets podcast episode, learn about the key considerations, mechanics and timelines of going public on a US exchange.  Topics in this podcast include:  An…

Drug Development in Obesity

Apr 30, 2024 26m

Guests: Pete Bak and Christian Thienel Length: 27 minutes In this episode of The Life Science Report, Dr. Pete Bak and Back Bay Director, Christian Thienel catch up on the area attracting the most…

The Current Dynamics in Capital Markets

Apr 15, 2024 22m

Welcome to another episode with the DNB//Back Bay Partnership for Healthcare.In this episode Jonathan Gertler, Back Bay CEO and Managing Partner, is once again joined by James Cirenza, Head of Fixed…

Vaccine Developments 2024: A Podcast Discussion on Latest Vaccine Technology and Ongoing Clinical Developments

Mar 18, 2024 37m

Guests: Pete Bak and Christian Thienel Length: 37 minutes With the advent of COVID-19 in 2020 and 2021, we saw a tremendous amount of interest in not only COVID vaccines, but other companies riding…

Trends and Investment Activity in Radiopharmaceuticals and Psychedelics

Feb 14, 2024 25m

A Podcast Discussion on the Trends and Investment Activity in Radiopharmaceuticals and PsychedelicsGuests: Pete Bak and Christian ThienelLength: 25 minutesHere at Back Bay we’ve seen a number of…

Vertex’s Exa-cel to Biogen and Sage’s Zurzuvae: Notable Product Approvals of 2023

Jan 03, 2024 25m

As we move into 2024, Back Bay’s strategic advisors summarize key product approvals from three classes and indications over this past year, including the December CRISPR and Vertex approval of…

Monthly Roundup of News from Healthcare Development

Nov 07, 2023 30m

In our latest podcast, Back Bay Life Science Advisors focused on the chronic and rare disease development of kidney disease. Recently, there have been some changes in treatment, some recent…

The Current and Future Landscape of Healthcare IPO Markets

Oct 27, 2023 23m

With the DNB//Back Bay Partnership for HealthcareIn the current markets, Healthcare continues to rally as the second-largest industry behind technology in the stock market, and in the US markets…

The Heart of the Matter: Behind the Renewed Interest in Cardiovascular Disease

Oct 12, 2023 24m

A conversation on the rising trends in the cardiology spaceCardiology has historically been a cornerstone of large pharmaceutical portfolios. The late 2000s and 2010s saw many pharmaceutical…

The Transactional Landscape Of ADCs: The Powerhouse of Antibody Drug Conjugates

Aug 29, 2023 25m

In this episode, Dr. Peter Bak is joined by Trent Gordon and Dr. Mavra Nasir as they discuss their Bioprocess Online article published earlier this year, “The Transactional Landscape of ADCs: A…

Investing in Health Tech & Digital Medicine: Expert Talk with Mikaela Odlander & Edward Kliphuis

Apr 14, 2023 29m

The world of health tech has changed dramatically since decades ago when physicians had to endure 11 keystrokes to prescribe a single aspirin. These days, AI-based radiology and AI-based pathology…

Contingencies for Biopharma, Medtech Deal Planning in a Down Market

Feb 09, 2023 28m

For biopharma and medtech companies developing new treatments, capital for advancement and growth is invariably dependent on strategic preparation, differentiation, and persistence. Good preparation…

Gene Editing to Cross-Species Transplantation: The Most Compelling Healthcare Stories of 2022

Jan 24, 2023 37m

In our first podcast episode of 2023, Back Bay’s strategic advisors summarize some of the most compelling healthcare development stories from 2022. From CRISPR and gene editing advancement to…

Frequently Asked Questions

How many episodes does Back Bay Life Science Report have?

Back Bay Life Science Report has published 35 episodes since June 2021, covering topics in Health & Fitness, Medicine.

Is Back Bay Life Science Report still active?

Back Bay Life Science Report is currently highly active with new episodes monthly. Average episode length is 26m.

How do I contact Back Bay Life Science Report for sponsorship or guest appearances?

Sign up on Grep.FM to access contact details for Back Bay Life Science Report, including email and social media links.

Similar Podcasts